2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Animal Model
PAPER

4123 Engineered receptor-directed fratricide enables selective elimination of pathogenic T cells across cellular therapies and T-cell malignancies

Filippo Birocchi, Jacob Schwartz2, Jessica A Frank3, Aiyana Parker4, Amanda A Bouffard5, Christopher Kelly6, Alexandra Bratt7, Viktoria Blumenberg8, Adele Mucci9, Yueyang Fan10, Amira Barkal11, Giulia Escobar12, Marcela V. Maus, MD, PhD13, Mark B. Leick, MD14
1 Harvard Medical School, Boston, Massachusetts, United States, MGH, Boston, Massachusetts, United States
2 MGH, Boston, Massachusetts, United States
3 Harvard Medical School, Boston, Massachusetts, United States, MGH, Boston, Massachusetts, United States
4 MGH, Boston, Massachusetts, United States
5 MGH, Boston, Massachusetts, United States
6 MGH, Boston, Massachusetts, United States
7 MGH, Boston, Massachusetts, United States
8 Harvard Medical School, Boston, Massachusetts, United States, MGH, Boston, Massachusetts, United States
9 Harvard Medical School, Boston, Massachusetts, United States, MGH, Boston, Massachusetts, United States
10 Harvard Medical School, Boston, Massachusetts, United States, MGH, Boston, Massachusetts, United States
11 Harvard Medical School, Boston, Massachusetts, United States, MGH, Boston, Massachusetts, United States
12 Harvard Medical School, Boston, Massachusetts, United States, MGH, Boston, Massachusetts, United States
13 Harvard Medical School, Boston, Massachusetts, United States, MGH, Boston, Massachusetts, United States
14 Harvard Medical School, Boston, Massachusetts, United States, MGH, Boston, Massachusetts, United States

Background
Selective depletion of pathogenic T cells remains a major challenge in hematology, both for controlling severe toxicities associated with adoptive cellular therapies and for treating T-cell malignancies. FDA-approved CAR-T products, including axicabtagene ciloleucel and ciltacabtagene autoleucel, can cause severe and potentially life-threatening toxicities that require rapid termination of CAR-T-cell activity, yet most approved products lack an off-the-shelf safety switch. In T-cell malignancies, selective elimination of malignant T cells is hindered by shared antigen expression with healthy T cells, resulting in T-cell aplasia, while TRBC1-directed CAR-T therapies are further complicated by reverse killing. We developed SHARKs (Synthetic Homodimer Activating Reciprocal Killing), a new class of receptor-directed biologics that induce reciprocal killing between T cells expressing a shared surface receptor, including chimeric antigen receptors (CARs) and endogenous T-cell receptors (TCRs).

Methods
SHARKs are homobivalent molecules composed of two identical receptor-binding domains that promote receptor cross-linking between neighboring cells, triggering immunological synapse formation and reciprocal killing. To extend serum persistence and enable Fc-mediated effector functions, we engineered Fc-fused SHARKs (SHARK-Fc) that retained receptor-directed fratricide activity. SHARKs were generated against conserved CAR-associated epitopes and the mutually exclusive TCR constant region isoforms TRBC1 and TRBC2, enabling selective elimination of malignant T-cell clones while preserving approximately half of the normal T-cell repertoire. Activity was evaluated using Jurkat reporter assays, primary human T cells, cytokine production, degranulation, viability assays, flow cytometry, and multiple in vivo models of CAR-T-cell toxicity and T-cell malignancy.

Results
SHARKs converted receptor engagement into productive cell-cell interactions, inducing immunological synapse formation, activation, cytokine secretion, degranulation, and reciprocal killing of receptor-expressing T cells. Unlike conventional monoclonal antibodies, SHARKs actively induced T-cell depletion through receptor cross-linking in trans rather than relying on endogenous immune effector mechanisms.

SHARKs targeting conserved CAR domains efficiently depleted CAR-T cells representing the architectures used across all FDA-approved CAR-T products. Anti-VHH SHARK-Fc depleted ciltacabtagene autoleucel-like CAR-T cells in vivo, rapidly terminating CAR-T-cell activity. SHARK rapidly depleted lisocabtagene maraleucel (Breyanzi)-like CAR-T cells in vivo and prevented lethal CLDN18.2-directed on-target/off-tumor toxicity. In this model, Fc-silent monoclonal antibodies recognizing the same CAR epitope failed to provide meaningful protection, highlighting the unique mechanism of receptor-directed fratricide. SHARK-Fc further prevented lethal ROR1- and GD2-directed CAR-T toxicities. In a humanized cytokine release syndrome model using hCD34-engrafted SGM3 mice treated with axicabtagene ciloleucel (axi-cel)-like CAR-T cells, SHARK-Fc abrogated CAR-T-associated weight loss and markedly reduced circulating IFN-γ, IL-6, and TNF-α.

To extend this strategy to T-cell malignancies, SHARKs targeting TRBC1 or TRBC2 selectively eliminated cells expressing the corresponding TCR constant region while preserving the reciprocal T-cell compartment. This selective depletion translated into therapeutic efficacy across multiple preclinical models of TRBC-defined leukemia and lymphoma, overcoming limitations of existing approaches.

Conclusions
SHARKs establish receptor-directed fratricide as a previously unrecognized mechanism for selective T-cell depletion. A single off-the-shelf platform enables rapid termination of pathogenic CAR-T cells while selectively eliminating TRBC-defined malignant T-cell populations, providing a broadly applicable therapeutic strategy across cellular therapies and T-cell malignancies.

Filippo Birocchi: No relevant conflicts of interest to declare.